The antitumour activity of olaparib indicated in this trial, in patients with metastatic castration-resistant prostate cancer with both germline and somatic aberrations of BRCA2, now supports the implementation of NGS testing of tumour samples. This evidence concerns the gene BRCA2 and prostate cancer.